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Abstract
Background: Enadenotucirev is a chimeric adenovirus with demonstrated preclinical tumor-selective cytotoxicity
and a short half-life. Further clinical mechanism of action data showed that enadenotucirev can gain access to and
replicate within different types of epithelial tumors. This phase 1 dose escalation study assessed intravenous (IV)
dose escalation with enadenotucirev to establish the maximum tolerated dose (MTD) and subsequently identify a
suitable schedule for repeated cycles.
Methods: Sixty-one patients with advanced epithelial tumors unresponsive to conventional therapy were enrolled
and received enadenotucirev monotherapy as part of this study. During the phase 1a dose escalation (n = 22) and
expansion (n = 9), delivery of enadenotucirev between 1 × 1010 and 1 × 1013 viral particles (vp) on days 1, 3, and 5
(single cycle) was used to determine an appropriate MTD. Subsequent treatment cohorts (phase 1a, n = 6 and
phase 1b, n = 24) examined the feasibility of repeated dosing cycles in either 3-weekly or weekly dosing regimens.
Results: Enadenotucirev displayed a predictable and manageable safety profile at doses up to the MTD of 3 × 1012
vp, irrespective of infusion time or dosing schedule. The most commonly reported treatment-emergent adverse
events (TEAEs) of grade 3 or higher were hypoxia, lymphopenia, and neutropenia. The frequency of all TEAEs
(notably pyrexia and chills) was highest within 24 h of the first enadenotucirev infusion and decreased upon
subsequent dosing. Additionally, delivery of three doses of enadenotucirev over 5 days optimized pharmacokinetic
and chemokine profiles in the circulation over time.
Conclusions: This study provides key clinical data in patients with solid epithelial tumors following treatment with
IV enadenotucirev monotherapy and supports further investigation of enadenotucirev in combination with other
therapeutic agents at doses up to the MTD of 3 × 1012 vp.
Trial registration: (ClinicalTrials.gov Identifier: NCT02028442). Trial registration date: 07 January 2014 –
Retrospectively registered.
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Background
The use of oncolytic viruses is rapidly emerging as a novel
therapeutic approach against cancer [1–4]. Such viruses
selectively infect tumor cells, directly killing infected cells
as well as initiating systemic antitumor immune responses
[5, 6]. Several oncolytic viruses are being tested in clinical
trials [7], either as monotherapies or as part of multimodal
therapeutics (e.g. in combination with immune checkpoint
inhibitors and chemotherapy) to synergize their activity
and improve outcomes for patients [2, 5].
Systemic delivery is a major goal in the field of oncolytic vi-
ruses [4]. Intravenous (IV) delivery of oncolytic viruses offers
advantages over intratumoral (IT) injection, including the op-
portunity to target inaccessible tumors and to treat both the
primary tumor and any overt or undiagnosed metastatic de-
posits simultaneously [8]. To date, talimogene laherparepvec,
an attenuated herpes simplex virus type-1, is the only oncoly-
tic virus therapy to be licensed by the European Medicines
Agency and the US Food and Drug Administration for the
local treatment of unresectable melanoma [9–11]. However,
talimogene laherparepvec is administered by IT injection,
restricting its use to accessible tumors and requiring specialist
skills, particularly when treating non-superficial tumors.
Enadenotucirev is a group B Ad11p/Ad3 chimeric oncoly-
tic adenovirus generated by directed evolution that has po-
tent and tumor-selective cytotoxicity, inducing a
non-apoptotic immunogenic death process [12, 13] and has
been shown to have antitumor efficacy in orthotopic human
tumor xenograft models [12, 14]. Furthermore, the original
derivation of the virus from a colorectal cell line, the high
level of activity in a range of colorectal cell lines and in vivo
[12] as well as findings from a parallel clinical study [15],
highlighted gastrointestinal and genitourinary malignancies
as specific indications of interest. Enadenotucirev was priori-
tized for clinical development and delivery by IV infusion on
the basis of preclinical evidence of its stability in human
whole blood [16, 17] and the low prevalence of neutralizing
antibodies against group B adenoviruses, including Ad11p
(the outer coat of enadenotucirev is exclusively the Ad11p
serotype), in the general population [18, 19].
Enadenotucirev is being tested in several trials in an
international clinical program. One of these studies (the
Mechanism of Action [MOA] study) demonstrated that
enadenotucirev can be successfully administered by IV in-
fusion or IT to a range of epithelial tumor types with a
predictable and manageable safety profile [15]. This study
also demonstrated that enadenotucirev gained access to
and replicated within tumors, and was associated with
high levels of CD8+ T-cells within the tumor nests [15].
We now report the primary findings of the phase 1 EValu-
ating OncoLytic Virus Efficacy (EVOLVE) study. EVOLVE
was designed to assess the safety and tolerability of enadeno-
tucirev dose escalation administered by IV infusion in pa-
tients with colorectal cancer (CRC) and other solid epithelial
tumors to determine the maximum tolerated dose (MTD),
as well as selecting a suitable schedule for repeat cycle IV in-
fusion in patients with metastatic CRC (mCRC) or urothelial
cell carcinoma (UCC).
Methods
Study design and dosing schedules
The EVOLVE study was a phase 1 (NCT02028442), mul-
ticenter, non-randomized, open-label study to investigate
the administration of enadenotucirev monotherapy in
patients with advanced or metastatic epithelial solid tu-
mors. The EVOLVE study design is shown in Fig. 1.
The study consisted of single-cycle dose escalation and
dose expansion cohorts and a repeat cycle cohort (phase 1a),
as well as additional optimal schedule-finding repeat cycle
cohorts (phase 1b). Key study decisions were taken by cen-
tralized study decision-making committees. Safety and toler-
ability data (as well as supporting laboratory data) were
reviewed at each point of study treatment adjustment by a
Clinical Events Committee (CEC). Safety data were reviewed
by a Data and Safety Monitoring Committee (DSMC) at the
end of phase 1a. Patients were followed up in phase 1a for 9
months and in phase 1b for overall survival.
All patients were screened in the 21 days before the start
of study treatment. The starting dose was 1 × 1010 viral parti-
cles (vp) infused over 5min, determined to allow a 40-fold
safety margin below the no observed adverse effect level
from the relevant Good Laboratory Practice toxicology study.
Three patients were enrolled sequentially with at least a
14-day window and followed up during the dose-limiting
toxicity (DLT) assessment period (28 days after the first ena-
denotucirev administration). If no DLTs were observed, the
next cohort was enrolled at a 10-fold higher dose. Expansion
of a cohort, from three to six patients, was required if one of
the three patients experienced a DLT at a given dose. If two
or more participants had a DLT at a given dose, then no fur-
ther patients received this dose and the previous lower dose
level was defined as the MTD. Adverse events (AEs) that
met any of the following criteria were considered DLTs if
they were treatment-related and confirmed to meet the DLT
criteria by the CEC.
 Grade 3 or higher non-hematological toxicity lasting
more than 3 days despite optimal supportive care,
except for:
– self-limiting or medically controllable toxicities
(e.g. nausea, vomiting, diarrhea, fatigue,
headache, chills, electrolyte disturbances,
hypersensitivity reactions) and alopecia.
 Not all enadenotucirev doses were administered
over the 5 days owing to AEs considered
treatment-related (cycle 1 only).
 Febrile neutropenia (the occurrence of an absolute
neutrophil count < 0.5 × 109/L concurrently with a
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temperature elevation of > 38.5 °C lasting more
than 5 days).
 Grade 4 neutropenia or thrombocytopenia lasting
more than 14 days.
In the dose expansion stage, the number of patients
treated at the MTD, determined by the CEC, was expanded
to 12 patients. The repeat cycle stage cohort was intro-
duced to evaluate the safety and tolerability of repeated
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Fig. 1 Patient disposition and study design. The phase 1 single-cycle dose escalation and dose expansion stages of EVOLVE were designed to
determine the MTD of enadenotucirev, given in one cycle (one administration on days 1, 3, and 5 and an end-of-study visit 56 days after the last
administration of enadenotucirev). a The phase 1a repeat cycle stage comprised up to four 21-day cycles and an end-of-study visit 28 days after
the last administration of enadenotucirev. b The phase 1b component was initiated to select a suitable schedule and dose for repeat cycles of
enadenotucirev in patients with mCRC or UCC. Phase 1b comprised up to six 21-day cycles, ending with an end-of-study visit 28 days after the
last administration of enadenotucirev. Please refer to the study design and dosing and patient enrollment sections of the methods and patient
demographics section of the results for full details of the enrollment into this phase. c Overall study design of the EVOLVE study. CRC colorectal
cancer, ECOG Eastern Cooperative Oncology Group, EVOLVE EValuating OncoLytic Virus Efficacy, IV intravenous, mCRC metastatic colorectal cancer,
MTD maximum tolerated dose, Q1W weekly schedule, Q3W 3-weekly schedule, UCC urothelial cell carcinoma, vp viral particle(s). aOne participant
later received one additional cycle of treatment. bThree participants received one or more additional cycles of treatment. cOne participant also
had inadequate bone marrow function
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3-weekly (Q3W) treatment cycles of enadenotucirev mono-
therapy. This cohort was initiated once six patients had
been followed up for at least 28 days after the day 5 admin-
istration of enadenotucirev in the dose expansion stage.
Phase 1b was initiated once six patients had been treated in
the phase 1a repeat cycle stage to further assess repeated
Q3W and weekly (Q1W) dosing schedules. A summary of
the dosing regimens used during EVOLVE is shown in
Additional file 1: Table S1.
Patient enrollment
Patients were eligible if they were aged 18 years or over
with an Eastern Cooperative Oncology Group performance
status of 0 or 1 and predicted life expectancy of 3months
or more with adequate renal, hepatic, and bone marrow
function and coagulation test results. Eligibility also re-
quired patients to have a gap of at least 3 weeks since their
last dose of IV systemic chemotherapy and 2weeks since
their last oral dose of capecitabine, with recovery to grade 1
from the effects (excluding alopecia) of any previous ther-
apy. Patients had to meet one of the following specific in-
clusion criteria for the different parts of the study.
 Dose escalation stage (in phase 1a): solid tumor of
epithelial origin not responding to standard therapy
or for which no standard treatment exists.
 Dose expansion and repeat cycles stages (phase 1a and
phase 1b): mCRC not responding to standard therapy
and no more than three previous lines of systemic
therapy for advanced disease, or no more than four
previous lines of systemic therapy for advanced disease
if one of the four lines was an anti-epidermal growth
factor receptor therapy given as a single agent or com-
bined with a previously administered chemotherapy
regimen. In phase 1b, patients with advanced or meta-
static UCC who had received no more than one
chemotherapy-containing regimen and one other sys-
temic biologic agent were also included.
Key exclusion criteria included any condition or illness
that would compromise safety or interfere with the evalu-
ation of the safety of the study treatment, significant im-
munodeficiency, splenectomy, previous allogeneic or
autologous bone marrow or organ transplantation, active
infections or viral disease, use of anti-viral agents in the last
14 days, major surgery in the last 4 weeks or radiotherapy
in the last 3 weeks, another primary malignancy in the last
3 years (except for non-melanoma skin cancer or cervical
cancer in situ), and a central nervous system metastasis that
was symptomatic and/or required treatment.
Clinical assessments
Demographic and baseline data were collected at screen-
ing. The incidence, nature, and severity of AEs were
characterized using the National Care Institute Common
Terminology Criteria for Adverse Events (CTCAE) Ver-
sion 4.03. Additionally, changes over time and maximum
changes in laboratory data were analyzed.
Although antitumor activity was not the primary out-
come of the study, the best overall response to enadenotu-
cirev was monitored using the Response Evaluation Criteria
in Solid Tumors (RECIST) Version 1.1, as assessed both by
the investigator and by an independent reviewer. Tumor
imaging was performed every 8 weeks (phase 1a) or every
9 weeks (phase 1b) until disease progression.
Kinetics of enadenotucirev
The concentration of enadenotucirev in the blood was
measured using quantitative polymerase chain reaction
(qPCR) to detect genomic viral DNA as described previ-
ously [15]. Whole blood samples were collected during
phase 1a on days 1, 3, and 5 pre-infusion, at the end of in-
fusion (EOI), and at regular intervals for up to 6 h after
EOI. Additional samples were obtained 24 h after EOI (on
days 2, 4, and 6) and on days 8, 15, 22, and 61. During
phase 1b, samples were taken pre-infusion, at EOI, and at
regular intervals for up to 4 h after EOI on days 1 and 5
during cycles 1 and 2 of the Q3W schedule and days 1, 5,
8, and 15 for the Q1W schedule. Samples were also col-
lected on all other dosing days pre-infusion and at EOI.
Analysis of enadenotucirev shedding
The concentration of shed enadenotucirev was quantified via
qPCR as described previously [15]. During phase 1a dose es-
calation, scheduled clinical samples were collected daily from
baseline to day 6 and then on days 8, 15, 22, and 61. During
dose expansion, samples were collected at baseline and on
days 3, 5, 8, 22, and 61. During phase 1b, samples were col-
lected on days 1, 5, 8, and 15 of cycles 1 and 2 and subse-
quently on days 1, 8, and 15 of cycles 3–6, and at the end of
treatment during both dosing schedules. Shedding assays
were performed on buccal and rectal samples in phase 1a,
and urine samples in both phase 1a and phase 1b.
Anti-enadenotucirev antibody response
Serum anti-enadenotucirev antibody response was assessed
using a Meso Scale Discovery (Meso Scale Diagnostics,
Rockville, MD, USA) enzyme-linked immunosorbent assay,
as described previously [15]. During phase 1a, dose escal-
ation and dose expansion stages, samples were collected
pre-infusion on day 1 and subsequently on days 8, 15, 22,
61, and 120. During the Q3W schedule of phase 1b, sam-
ples were collected pre-infusion on days 1 and 5 of cycles 1
and 3–6, days 1, 3, and 5 of cycle 2, as well as at the end of
treatment and follow-up visits. Samples were collected
pre-infusion during cycle 1 (days 1, 5, 8, and 15) and subse-
quently on day 1 of cycles 2–6, as well as at the end of
treatment and follow-up visit as part of the Q1W schedule.
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Viral infectivity assay
Blood samples were collected at EOI on each dosing
day. 100 μL of blood samples were added to monolayers
of HT-29 cells along with negative and positive controls.
The extent of infection was scored depending on viral
staining and monolayer destruction. If no staining of
cells or plaque formation was observed, the sample was
scored as negative.
Cytokine responses
Cytokine levels were assessed using a FlowCytomix assay
as part of phase 1a as previously described [15], and a
Luminex bead-based multiplex assay (R&D Systems,
Abingdon, UK) in phase 1b. During phase 1a dose escal-
ation, serum samples were collected immediately before
infusion, 6 and 12 h post-infusion on days 1, 3, and 5,
24 h post-infusion, and on day 8 (72 h post-day 5 infu-
sion). For dose expansion, samples were collected 6 and
12 h post-infusion on days 1, 3, and 5, as well as on day
8. In phase 1b, samples were collected pre-infusion and
6 h post-infusion, with an option to collect additional
samples 12 h post-infusion on all dosing days.
Enadenotucirev replication in tumor tissue
Hexon staining was assessed using immunohistochemis-
try with a pan hexon monoclonal antibody (ab8251,
Abcam, Cambridge, UK) as previously described [15].
Statistical analysis
Viral kinetic, pharmacodynamic, and safety data were
analyzed using descriptive statistics, frequency counts,
and percentages, and were also shown graphically, if ap-
propriate. Individual means were tested using Student’s
t-tests and multiple means were compared using
Tukey-Kramer honest significant difference analyses. A
post hoc analysis categorized treatment-emergent ad-
verse events (TEAEs) and laboratory test results by dose
level (< 1 × 1012 vp, 1–3 × 1012 vp, and > 3 × 1012 vp).
For this post hoc analysis, coding of all AEs was updated
to the latest version of the Medical Dictionary for Regu-
latory Activities, Version 19.1.
Results
Patient demographics, disposition
Patients were aged between 36 and 79 years, were pri-
marily men (75.4%), and all were Caucasian. During
phase 1a, 50 patients were screened for study eligibility
between September 24, 2012 and March 28, 2014 (Fig.
1a), of whom 37 were enrolled in the study and received
the study treatment. As part of the phase 1 dose escal-
ation, 22 of 24 patients (91.7%) received one cycle of
treatment (one administration on days 1, 3, and 5),
with the study treatment being withdrawn in two pa-
tients because of DLTs at the highest dose tested
(1 × 1013 vp). One patient withdrew consent during
the dose expansion stage of phase 1a, with eight of
nine patients (88.9%) completing the treatment period.
All patients (6/6) completed the repeat dosing cycle
treatment period in phase 1a.
Phase 1b screened 31 patients between November 3,
2014 and March 29, 2016 (Fig. 1b); 24 were enrolled and
received enadenotucirev. Twenty patients (83.3%) re-
ceived all doses in cycle 1, 15 patients (62.5%) received
all doses in cycle 2, and 13 patients (54.2%) received all
doses in cycle 3. Three patients continued treatment be-
yond cycle 3, with one patient receiving all doses until
cycle 5 day 8 on the Q1W schedule and two patients
(8.3%) completing all six cycles of treatment, one on
each of the dosing schedules. During treatment, 22 pa-
tients discontinued treatment because of disease pro-
gression (16 patients), toxicity (four patients), or
withdrawal of consent from study treatment or investi-
gator decision due to an unrelated AE concurrent with
disease progression (one patient each).
MTD and safety
Having increased the dose in 10-fold increments starting
at 1 × 1010 vp/5 min, no DLTs were elicited at doses up
to 1 × 1012 vp. Two DLTs were experienced in response
to the 1 × 1013 vp/5 min dose (cohort 4). One patient de-
veloped hypoxia and dyspnea and a second acute lung
injury (CTCAE grade 3); both DLTs were considered
treatment-related and resulted in treatment discontinu-
ation after the first dose. The dose investigated was sub-
sequently de-escalated to 3 × 1012 vp (cohorts 5 and 6)
and later re-escalated to 6 × 1012 vp (cohort 7). The infu-
sion durations of cohorts 6 and 7 were increased to pro-
vide an infusion rate comparable to cohort 3, and the
MTD was determined to be 6 × 1012 vp/40 min.
However, after initiation of phase 1b and following re-
view of the additional safety data generated in this part
of the study, the CEC and DSMC recommended redu-
cing the dose for both dosing schedules (Q3W and
Q1W) to 3 × 1012 vp/15 min owing to the overall fre-
quency and severity of TEAEs (including severe hypoxia
and raised hepatic transaminases) across the two initial
phase 1b cohorts at the 6 × 1012 vp/40 min dose. At the
end of the study, the investigators considered the MTD
to be 3 × 1012 vp, irrespective of infusion time or dosing
schedule.
Most patients experienced TEAEs during the first
week of treatment, usually within 24 h of dosing. The
overall incidence of TEAEs was generally higher during
cycle 1 than during cycle 2. Preferred terms describing
primary influenza-like symptoms (pyrexia, chills, and
influenza-like illness) were among the most commonly
reported, by 45 (73.8%), 41 (67.2%), and 13 (21.3%) pa-
tients, respectively. All chills and influenza-like illness
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events were grade 1 or 2, and only two patients (receiv-
ing 6 × 1012 vp) experienced grade 3 pyrexia, with none
being considered a serious AE or leading to dose discon-
tinuation (Table 1). A greater number of these TEAEs
relating to influenza-like symptoms were reported within
24 h of the first cycle 1 dose than after the second or
third doses, and the overall frequency was higher follow-
ing the first dose in cycle 1 than following the initial
doses of cycle 2.
Gastrointestinal symptoms such as nausea, vomiting,
and diarrhea may also be attributable to an inflammatory
response to vp infusion. Nausea and vomiting were both
reported by 24 patients (39.3%), with an increase in fre-
quency seen at doses of 1 × 1012 vp and above. Most of
these events were not considered to be treatment-related
and all were CTCAE grade 1 or 2. The incidence of diar-
rhea was predominantly seen at doses above 3 × 1012 vp.
Nausea and vomiting appeared dose-related, with an in-
crease in frequency at doses of 1 × 1012 vp and above.
Reporting of acute respiratory symptoms encompassed
acute lung injury, dyspnea, hypoxia, and interstitial lung
disease. The vast majority of acute lung injury, hypoxia,
and interstitial lung disease events occurred at doses
above 3 × 1012 vp (Table 1). All but one of the six pa-
tients experiencing hypoxia had severe CTCAE grade 3
events. Dyspnea was reported across the dosing range;
however, these events were mild to moderate in nature
at doses of 3 × 1012 vp or below.
Assessment of renal function revealed that TEAEs of
renal failure and acute renal injury considered
treatment-related occurred at doses above 3 × 1012 vp.
One patient developed treatment-related nephrotic syn-
drome after treatment with 3 × 1012 vp. In addition to
five patients (17.2%) at doses higher than 3 × 1012 vp,
four patients (15.4%) receiving 3 × 1012 vp had protein-
uria considered treatment-related.
Investigations relating to changes in hepatic function
(increased transaminases) were seen more commonly at
doses above 3 × 1012 vp. These were considered
treatment-related in three patients (11.5%) receiving 3 ×
1012 vp and 12 patients (41.4%) at doses above 3 × 1012 vp.
The most common laboratory investigations relating to
coagulation events were increased fibrin D-dimer levels
and prolonged activated partial thromboplastin time.
These events were not reported at doses below 3 × 1012 vp
but were reported in 14 (23%) and seven patients (11.5%)
at doses of 3 × 1012 and above, which were considered
treatment-related in 12 (19.7%) and six patients (9.8%), re-
spectively. Anemia was observed across the dose range
but most cases were not considered treatment-related.
Falls in total white blood cell count were seen at doses of
1 × 1012 vp and above, and the proportion of patients with
neutropenia increased with dose (two patients [7.7%] at
doses of ≤ 3 × 1012 vp compared with five patients [17.2%]
at doses > 3 × 1012 vp), and all were considered
treatment-related. Likewise, decreased platelet counts in-
creased with dose (six patients [18.8%] at doses of ≤ 3 ×
1012 vp compared with 13 patients [44.8%]) at doses > 3 ×
1012 vp). Falls in platelet count (reported as either
thrombocytopenia or platelet count decreased) were ob-
served in 19 patients (31.1%) and considered
treatment-related in all patients (Table 1).
Intestinal obstruction (reported as gastrointestinal ob-
struction, small intestinal obstruction, and intestinal ob-
struction) was reported in seven patients, all at doses of 3 ×
1012 vp and above. In all cases, there were predisposing fac-
tors but it was considered treatment-related in two patients
treated as part of phase 1b. Abdominal pain and abdominal
pain upper were reported by 13 patients (21.3%), predomin-
antly at doses of 3 × 1012 vp and above. These events were
considered treatment-related in five patients.
Enadenotucirev pharmacokinetics
In line with data from theoretical modeling (Fig. 2a), upon
enadenotucirev infusion, blood virus concentration kinetics
fit to a one-phase decay with a dose-independent alpha
half-life of 16.7min. There was no significant change in
mean half-life of virus clearance observed on day 1 in re-
sponse to increasing doses (Additional file 2: Figure S1a).
Thus, it was concluded that half-life is dose-independent
over the study range. Subsequent comparison of doses
showed no significant differences in alpha half-life on days
1, 3, and 5 (Fig. 2b), when repeated doses were adminis-
tered on either Q3W or Q1W infusion schedules (Add-
itional file 2: Figure S1b), or at different doses (Additional
file 2: Figure S1c). There was, however, a significant in-
crease in maximum serum concentration (Cmax) between
days 1 and 5 (Fig. 2c; p < 0.0001) of cycle 1. By day 61, gen-
omic DNA levels had dropped to below the level of quanti-
fication (LOQ) in 26/28 (92.9%) blood samples (Fig. 2d).
The qPCR signal may, however, comprise infectious,
non-infectious, and/or broken-down viral products con-
taining the relevant DNA sequence. Evidence of active
virus came from an additional investigation of one patient
with mCRC, who had abdominal wall metastases biopsied
39 days after the last enadenotucirev dose (following four
cycles of 6 × 1012 vp in a Q3W schedule), which showed
extensive areas of cell necrosis and evidence of viral repli-
cation (Additional file 2: Figure S2). These findings are
consistent with results from the MOA study [15].
Post-infusion viral shedding
Buccal shedding (phase 1a) was detected at all doses in
all but six patients, and shedding frequency and concen-
tration were generally related to infusion concentration
(Fig. 3a). Shedding was most common between day 6
and day 8, which is equivalent to 24–72 h after the final
dose of enadenotucirev.
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Rectal shedding (phase 1a) was related to dose level,
detected in all but the lowest dosing cohort (1 × 1010
vp), and overall in 17 of the 31 patients (Fig. 3b). Viral
DNA was most commonly observed in the rectal swabs
between day 4 and day 8 (24–72 h following the final
dose of enadenotucirev).
Urine shedding (phase 1a and phase 1b) could be detected
in all samples; however, for phase 1a, this was only at low
concentrations because no legitimate samples gave a concen-
tration above the LOQ (Additional file 2: Figure S3a). In
phase 1b, shedding was observed only above the LOQ in
two samples (Additional file 2: Figure S3b). This was seen in
one patient who had UCC and had not had their bladder re-
moved. A relatively large concentration of viral DNA was
seen in the urine 48 h after initial dosing, which may have
been the result of viral replication in a penetrating tumor.
Antibody response to enadenotucirev in phase 1b
Before dosing, most patients had no or very low levels of
anti-enadenotucirev antibodies. Following enadenotucirev in-
fusion, all patients showed an increase in antibody titer from
baseline, irrespective of dose and schedule (Fig. 4). This in-
crease plateaued by day 20 (for all patient groups, individual
variations were noted) and was sustained thereafter.
a
b
d
c
Fig. 2 Blood viral kinetics and mean enadenotucirev concentration in blood by cohort. a Theoretical day 1 kinetics of enadenotucirev. b Box plot
showing the mean (and 95% CI) half-life across dosing cohorts of EVOLVE phase 1a on dosing days 1, 3, and 5. c Fold change increase in Cmax
across dose administrations. The red box represents outlier box plot quantile analysis, and the green diamond represents mean and 95% CI
across dosing cohorts of EVOLVE phase 1a on dosing days 1, 3, and 5. d Mean (± SD) enadenotucirev blood concentration by cohort. CI
confidence interval, Cmax maximum serum concentration, EOI end of infusion, EVOLVE EValuating OncoLytic Virus Efficacy, LOQ level of
quantification, SD standard deviation, vp viral particle(s)
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To evaluate the potential impact of this antibody re-
sponse on enadenotucirev infectivity in the blood,
post-infusion samples were tested in a virus infectivity
assay (Table 2 and Additional file 2: Figure S4). Strong
virus infectivity was observed in all (14/14) samples col-
lected following infusion on day 1, cycle 1. Viable virus
infectivity was also observed in samples from 12/15 pa-
tients (80%) on day 1, cycle 2 (day 22). Subsequent as-
sessment on day 1, cycle 3 revealed that samples from
fewer patients (3/12 [25%]) displayed infectivity (day 43).
Cytokine response to enadenotucirev
Analysis was limited to the cytokines that produced the
most robust response on cycle 1, day 1 (i.e. interferon
[IFN]-γ, interleukin [IL]-6, monocyte chemoattractant
protein [MCP]-1, and tumor necrosis factor [TNF]-α).
Transient increases were observed after the first dose in
most patients, and these were dose-dependent (Fig. 5a–
d). When elevated cytokine levels were observed in a pa-
tient following the initial dose, subsequent administra-
tions on days 3 and 5 generally resulted in lower
responses (Fig. 5a–d). These lower cytokine responses
extended to multiple repeat-dose administrations per-
formed within a 2–3-day window of previous doses, and
continued, albeit to a lesser extent, if repeat dosing was
performed within 7–17 days. This suppressive effect was
diminished beyond cycle 2, with mean cytokine re-
sponses increasing more following 17-day (Q3W sched-
ule) than 7-day (Q1W schedule) delays in treatment
(Additional file 2: Figure S5a, c). This was, however, not
a
b
Fig. 3 Post-infusion viral shedding during phase 1a. a Mean buccal shedding as quantified by qPCR with solid bars representing the mean and
error bars representing the range observed. The number of patients in whom buccal shedding was detected (N; > 0 vp/μL) is represented by N.
The total number of samples represents the number of samples taken at each time point. The proportion positive is the percentage of samples in
which buccal shedding was detected across all cohorts. b Mean rectal shedding as quantified by qPCR with bars representing the mean and
error bars the range observed. The number of patients in whom rectal shedding was detected (N; > 0 vp/μL) is represented by N. The total
number of samples represents the number of samples taken at each time point. The proportion positive is the percentage of samples in which
buccal shedding was detected across all cohorts. LOQ level of quantification, N number, qPCR quantitative polymerase chain reaction, vp
viral particle(s)
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observed across all cytokines analyzed (Additional file 2:
Figure S5b, d).
Enadenotucirev dosing on subsequent days (i.e. day 3/5)
was associated with a reduced frequency of TEAEs per dose
during cycle 1 (Fig. 5e). A reduction was also observed in
the total number of events on cycle 2, day 1, compared with
cycle 1, day 1 (Additional file 2: Figure S5e).
Enadenotucirev efficacy
This phase 1 study was not designed to assess efficacy, but
stable disease lasting for more than 12 weeks was recorded
in five patients by both independent and investigator as-
sessment (per RECIST v1; Additional file 1: Table S2).
Discussion
EVOLVE was the first study initiated, although the second
to report, within the ongoing enadenotucirev clinical pro-
gram, initially planned as a phase 1/2 multicenter,
open-label clinical study investigating single- and
repeat-cycle dosing of enadenotucirev monotherapy. The
disposition of patients observed was not entirely unex-
pected in this heavily pre-treated, typical phase 1 patient
population. By the end of the study, the MTD was deter-
mined to be 3 × 1012 vp, irrespective of infusion duration or
dosing schedule. Most patients at this MTD experienced
inflammatory influenza-like events, which are typical of
oncolytic virus exposure, within 24 h of dosing; these, how-
ever, were manageable with appropriate treatment.
The data from EVOLVE provide additional insights
into enadenotucirev dosing that relate to the safety and
tolerability of repeat-dose scheduling. Of note was the
reduced frequency of TEAEs during subsequent treat-
ment cycles compared with those observed within 24 h
of cycle 1, day 1. The potential to schedule a lower dose
on day 1 followed by a higher dose on days 3 and 5 is
therefore worthy of further investigation. During previ-
ous studies of systemically administered viruses, changes
in the cytokine profile (notably IL-6) have correlated
with signs of toxicity [20]. Herein, increases in circulat-
ing cytokine levels (notably IFN-γ, IL-6, MCP-1, and
TNF-α) were observed following the first infusion, but
were attenuated in response to further infusions (days 3
and 5). These attenuated cytokine responses also con-
firm preclinical observations that informed the dosing
schedule used as part of this study [17]. These findings
were also consistent across Q3W and Q1W dosing
schedules during the first three treatment cycles. There-
fore, management of early AE manifestations by setting
the initial dose to be lower than subsequent doses may
prove advantageous.
Fig. 4 Summary of anti-enadenotucirev antibody response. Scatter plot of anti-enadenotucirev antibody titer over time, with the blue line
representing the moving mean
Table 2 Summary table of results from viral infectivity assay
Time point Negative,a
n (%)
Positive,a n (%) Total number of patient
samples analyzedCells stain positive for virus Plaques in monolayer Complete/ partial monolayer
destruction or quantifiable
Cycle 1,
day 1 (day 0)
0 (0) 0 0 14 (100) 14
Cycle 2, day 1 (day 22) 3 (20) 0 4 (26.7) 8 (53.3) 15
Cycle 3, day 1 (day 43) 9 (75) 3 (25) 0 0 12
aExample images for each level of infectivity are provided in Additional file 2: Figure S5
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The EVOLVE study represents the first assessment of
the pharmacokinetic behavior of a systemically adminis-
tered group B adenovirus in humans. The use of a clus-
tered administration regimen (three doses given in 5
days) resulted in a modest increase in Cmax on day 5
relative to after the first dose. The increase was greater
than can be explained by accumulation alone and is con-
sistent with a response to the initial virus dose leading
to suppression of virus clearance activity by cells of the
macrophage lineage, such as Kupffer cells in the liver.
However, no change in half-life was observed, which
may be due to the sensitivity of the assay and sampling
schedule used. This increase in circulating virus loading
occurred in addition to the diminished induction of
blood cytokine responses and side effect manifestation.
These findings are consistent with the hypothesis that
innate immune cells can be desensitized, allowing im-
proved delivery and fewer side effects with subsequent
doses.
The EVOLVE study provided further evidence of the
advantages of enadenotucirev in the context of IV dosing
with oncolytic viruses. Consistent with previous reports
a b
c
e
d
Fig. 5 Cytokine levels in the blood by infusion dose during phase 1a. a Mean concentration of IFN-γ by dose. b Mean concentration of IL-6 by
dose. c Mean concentration of MCP-1 by dose. d Mean concentration of TNF-α by dose. e Frequency of TEAEs (including any of chills, influenza-
like illness, and pyrexia) per dose occurring within 24 h of infusion on cycle 1, day 1 or following infusion on day 3/5. IFN interferon, IL interleukin,
MCP monocyte chemoattractant protein, TEAE treatment-emergent adverse event, TNF tumor necrosis factor, vp viral particle(s)
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of group B adenoviruses in the general population [18,
19], a low prevalence of neutralizing antibodies was ob-
served before initial dosing with enadenotucirev. An
antibody response was observed in most patients during
the EVOLVE study, with antibody titers plateauing ap-
proximately 20 days after first exposure. Despite this
antibody response, live virus could still be detected in
the blood of most participants following the second
cycle, indicating virus availability. However, the virus ac-
tivity was lower at cycle 2 than cycle 1 and declined fur-
ther by cycle 3, suggesting that the overall affinity of the
antibody response might be increasing, leading to an in-
crease in overall neutralizing activity. However, it is not
known whether, or to what extent these antibodies may
interfere with virus delivery to and activity within tu-
mors. Furthermore, detection of enadenotucirev in the
metastatic lesion presented herein and findings from our
previous MOA study suggest persistence within the
tumor [15], thereby potentially reducing the need for
frequent repeat dosing.
Taken together, these observations will inform the on-
going clinical program evaluating enadenotucirev (1–3 ×
1012 vp) in combination with additional cancer therapeu-
tics. Further investigations into the potential of enadeno-
tucirev will take advantage of this unique platform to
incorporate transgene add-ons and use systemic dosing to
deliver therapeutic agents to the tumor microenviron-
ment. Further modifications have utilized
matrix-degrading enzymes to remove interstitial barriers
and to improve the spread of enadenotucirev between
tumor ‘islands’ [21]. Additionally, enadenotucirev has been
engineered to express a range of biotherapeutic molecules
singly and in combination [14]. One example is the ex-
pression of a bispecific T-cell engager (BiTE), facilitating
the clustering and activation of CD4 and CD8+ T cells
[22]. A major advantage of this system is that BiTE (or
other transgene) transcription can be supressed until acti-
vation of the virus’ major late promoter, conferring specifi-
city to cancer cells in which viral replication is occurring.
One factor that is common to the most successful
oncolytic viruses developed to date is the capacity to
provoke anticancer immune responses. Mechanisms by
which tissues are protected from immune response hy-
peractivation can, however, be co-opted by tumor cells
to avoid destruction [23, 24]. Indeed, signaling adapta-
tions that occur upon recognition of its ligand by pro-
grammed cell death protein 1 (PD-1) within the tumor
microenvironment represent a major mechanism of im-
mune resistance [25, 26]. The evidence generated during
both the MOA and EVOLVE studies has highlighted the
recruitment of CD8+ T cells to the tumor microenviron-
ment, strongly suggesting the potential benefit of com-
bining enadenotucirev with PD-1 checkpoint blockade
[15]. Indeed, such synergy has recently been shown in a
study using a combination of talimogene laherparepvec
and the PD-1 inhibitor pembrolizumab in patients with
advanced melanoma [24]. The safety and tolerability of
IV enadenotucirev combined with the PD-1 inhibitor
nivolumab is currently being tested for the treatment of
epithelial carcinomas as part of the phase 1 trial SPICE
(NCT02636036) [27].
With the knowledge that most cancer patients receive
standard-of-care chemotherapies, exploring the potential
synergy between such agents and enadenotucirev may
prove clinically relevant. The potential of viral–chemo-
therapy combinations has also been demonstrated, with
paclitaxel in particular shown to increase the replicative
potential of adenoviruses [28]. Therefore, the combination
of enadenotucirev and paclitaxel is currently being tested
for the treatment of platinum-resistant ovarian cancer as
part of the phase 1 OCTAVE study (NCT02028117) [29].
Conclusions
Taken together, the results from EVOLVE showed that
enadenotucirev monotherapy can be administered in a
single cycle or repeated cycles with manageable toler-
ability. These findings also confirm previous observa-
tions of enadenotucirev’s low immunogenicity, short
half-life in the circulation, and consistent viral clearance
over repeated cycles. While only limited information was
gained with respect to the antitumor activity of enadeno-
tucirev monotherapy, the safety information will inform
future studies utilizing systemic delivery of combinator-
ial therapies.
Additional files
Additional file 1: Table S1. Summary table of dosing cohorts. Table S2.
Independent assessment of best overall response (per RECIST). (DOCX 43 kb)
Additional file 2: Figure S1. Comparison of viral kinetics following
different doses and schedules. a Scatter plot of calculated half-life of
enadenotucirev in blood in cycle 1, day 1 (phase 1a) by dose. The red box
represents outlier box plot quantile analysis, and the green diamonds
represent mean and 95% CI at each dose. b Scatter plot of viral clearance
half-life by schedule in phase 1b. The horizontal line represents the mean of
each schedule. c Scatter plot of viral clearance half-life for each patient on
each visit, coloured by dose (horizontal lines represent the mean half-life for
each dose at each time point). Figure S2. Biopsy of skin metastasis after
treatment with enadenotucirev. Skin biopsy taken after four cycles of
enadenotucirev dosing (6 × 1012 vp, Q3W), 107 days after first exposure (39
days after final dose). Figure S3. Mean urine viral shedding. As quantified
by qPCR with bars representing the mean and error bars representing a the
range observed by dose during phase 1a and b by schedule in phase 1b.
Figure S4. Representative viral infectivity assay images. Images taken during
the viral infectivity assay displaying a negative, b cells stained positive for
virus, c plaques in monolayer, and d complete/partial monolayer destruction
or quantifiable scoring. Figure S5. Cytokine levels in the blood by dosing
schedule during phase 1b. As measured using a Luminex bead-based
multiplex assay. a Mean concentration of IFN-γ by schedule. b Mean
concentration of IL-6 by schedule. c Mean MCP-1 concentration by
schedule. d Mean TNF-α concentration by schedule. e Total number of
TEAEs of interest (any of chills, influenza-like illness, and pyrexia) occurring
within 24 h of infusion across cycles. (DOCX 3593 kb)
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